Genital Diseases, Female  >>  everolimus  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
everolimus / Generic mfg.
NCT00703807: Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

Checkmark In combination with oral topotecan for recurrent & adv endometrial cancer
Feb 2014 - Feb 2014: In combination with oral topotecan for recurrent & adv endometrial cancer
Completed
1
10
US
Topotecan, Hycamtin, RAD001, Everolimus
Yale University, Novartis
Endometrial Cancer
05/10
05/10
NCT00967928: Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer

Withdrawn
1
0
US
RAD001, Afinitor, Everolimus, Cisplatin, CDDP, Platinol, External Beam Whole Pelvis Radiation Therapy
Accelerated Community Oncology Research Network, Novartis Pharmaceuticals
Cervical Cancer
12/10
12/10
PHOENIX I, NCT01217177: A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

Completed
1
14
RoW
everolimus, RAD001
Novartis Pharmaceuticals
Locally Advanced Cervical Cancer
04/14
04/14

Download Options